The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Guérin (BCG) immunotherapy outcome in bladder cancer: Establishment of a predictive profile in a Southern Europe population

BJU International

Volumn 116, Issue 5, 2015, Pages 753-763

  Lima, Luís ^a,b,c,d   Oliveira, Daniela ^a   Ferreira, José A ^a,e   Tavares, Ana ^a   Cruz, Ricardo ^a   Medeiros, Rui ^a,b,d,f   Santos, Lúcio ^a,f  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c POLYTECHNIC INSTITUTE OF PORTO   (Portugal)

^d LPCC   (Portugal)

^e UNIVERSITY OF AVEIRO   (Portugal)

^f UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

BCG immunotherapy; bladder cancer; polymorphisms; predictive profile; risk score of recurrence

Indexed keywords

BCG VACCINE; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CCR2; FAS LIGAND; IA ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 18 RECEPTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; FASLG PROTEIN, HUMAN; IL17A PROTEIN, HUMAN; IL17RA PROTEIN, HUMAN; IL18R1 PROTEIN, HUMAN; IL2RA PROTEIN, HUMAN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA;

ADULT; AGED; ANTIGEN PRESENTATION; ARTICLE; BLADDER CANCER; BLOOD SAMPLING; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; FEMALE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTHERN EUROPE; TREATMENT RESPONSE; CASE CONTROL STUDY; CAUCASIAN; DRUG EFFECTS; EPIDEMIOLOGY; EUROPE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; INTRAVESICAL DRUG ADMINISTRATION; PROCEDURES; TREATMENT OUTCOME; TUMOR RECURRENCE; URINARY BLADDER NEOPLASMS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; BCG VACCINE; CASE-CONTROL STUDIES; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FAS LIGAND PROTEIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-17; INTERLEUKIN-18 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, INTERLEUKIN-17; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; URINARY BLADDER NEOPLASMS;

EID: 84943581018     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12844     Document Type: Article

References (44)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917
2. Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 2009; 27: 295-300
3. Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013; 64: 639-653
4. Ehdaie B, Sylvester R, Herr HW,. Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol 2013; 64: 579-585
5. Witjes JA,. Management of BCG failures in superficial bladder cancer: a review. Eur Urol 2006; 49: 790-797
6. Alexandroff AB, Nicholson S, Patel PM, Jackson AM,. Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer. Immunotherapy 2010; 2: 551-560
7. Kuroda K, Brown EJ, Telle WB, Russell DG, Ratliff TL,. Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells. J Clin Invest 1993; 91: 69-76
8. Bevers RF, Kurth KH, Schamhart DH,. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer 2004; 91: 607-612
9. Ikeda N, Toida I, Iwasaki A, Kawai K, Akaza H,. Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Guerin (BCG): a role of BCG internalization into tumor cells. Int J Urol 2002; 9: 29-35
10. Bohle A, Brandau S,. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003; 170: 964-969
11. Askeland EJ, Newton MR, O'Donnell MA, Luo Y,. Bladder cancer immunotherapy: BCG and beyond. Adv Urol 2012; 2012: 181987
12. Luo Y,. Blocking IL-10 enhances bacillus Calmette-Guerin induced T helper Type 1 immune responses and anti-bladder cancer immunity. Oncoimmunology 2012; 1: 1183-1185
13. Shah G, Zhang G, Chen F, Cao Y, Kalyanaraman B, See WA,. iNOS expression and NO production contribute to the direct effects of BCG on urothelial carcinoma cell biology. Urol Oncol 2014; 32: 45.e1-459
14. Rosevear HM, Lightfoot AJ, O'Donnell MA, Griffith TS,. The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guerin (BCG) immunotherapy for urothelial carcinoma of the bladder. Cancer Metastasis Rev 2009; 28: 345-353
15. Brandau S, Suttmann H, Riemensberger J, et al. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guerin-activated killer cells. Clin Cancer Res 2000; 6: 3729-3738
16. Lima L, Dinis-Ribeiro M, Longatto-Filho A, Santos L,. Predictive biomarkers of bacillus calmette-guerin immunotherapy response in bladder cancer: where are we now? Adv Urol 2012; 2012: 232609
17. Gu J, Grossman HB, Dinney CP, Wu X,. The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence. Pharmacogenomics 2005; 6: 575-584
18. Lima L, Ferreira JA, Tavares A, et al. FASL polymorphism is associated with response to bacillus Calmette-Guerin immunotherapy in bladder cancer. Urol Oncol 2014; 32: 44.e1-447
19. Oosterlinck W, van der Meijden A, Sylvester R, et al. Guidelines on TaT1 (Non-muscle invasive) bladder cancer. EAU guidelines, 2006. Available at: http://www.uroweb.org/gls/pdf/05%20Non-muscle%20Invasive%20BC-TaT1-LR.pdf. Accessed December 2014
20. Lima L, Morais A, Lobo F, Calais-da-Silva FM, Calais-da-Silva FE, Medeiros R,. Association between FAS polymorphism and prostate cancer development. Prostate Cancer Prostatic Dis 2008; 11: 94-98
21. Harrell FE Jr, Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387
22. Zuiverloon TC, Nieuweboer AJ, Vékony H, Kirkels WJ, Bangma CH, Zwarthoff EC,. Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 2012; 61: 128-145
23. Lima L, Oliveira D, Tavares A, et al. The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure. Urol Oncol 2014; 32: 449-457
24. Lima L, Severino PF, Silva M, et al. Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy. Br J Cancer 2013; 109: 2106-2114
25. Lima L, Silva J, Amaro T, et al. IL-4 and TNF-alpha polymorphisms are associated with risk of multiple superficial tumors or carcinoma in situ development. Urol Int 2011; 87: 457-463
26. Ahirwar DK, Mandhani A, Dharaskar A, Kesarwani P, Mittal RD,. Association of tumour necrosis factor-alpha gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Guerin immunotherapy. BJU Int 2009; 104: 867-873
27. Ahirwar DK, Mandhani A, Mittal RD,. IL-8 -251 T > A polymorphism is associated with bladder cancer susceptibility and outcome after BCG immunotherapy in a northern Indian cohort. Arch Med Res 2010; 41: 97-103
28. Jaiswal PK, Singh V, Srivastava P, Mittal RD,. Association of IL-12, IL-18 variants and serum IL-18 with bladder cancer susceptibility in North Indian population. Gene 2013; 519: 128-134
29. Witkowska AM, Borawska MH,. Soluble intercellular adhesion molecule-1 (sICAM-1): an overview. Eur Cytokine Netw 2004; 15: 91-98
30. Becker JC, Termeer C, Schmidt RE, Brocker EB,. Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol 1993; 151: 7224-7232
31. Becker JC, Dummer R, Hartmann AA, Burg G, Schmidt RE,. Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J Immunol 1991; 147: 4398-4401
32. Bielinski SJ, Reiner AP, Nickerson D, et al. Polymorphisms in the ICAM1 gene predict circulating soluble intercellular adhesion molecule-1(sICAM-1). Atherosclerosis 2011; 216: 390-394
33. Takeuchi A, Dejima T, Yamada H, et al. IL-17 production by gammadelta T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guerin treatment against bladder cancer. Eur J Immunol 2011; 41: 246-251
34. Li N, Zhu Q, Li Z, et al. IL17A gene polymorphisms, serum IL-17A and IgE levels, and hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. Mol Carcinog 2014; 53: 447-457
35. Knevel R, de Rooy DP, Zhernakova A, et al. Association of variants in IL2RA with progression of joint destruction in rheumatoid arthritis. Arthritis Rheum 2013; 65: 1684-1693
36. Luo Y, Yamada H, Evanoff DP, Chen X,. Role of Th1-stimulating cytokines in bacillus Calmette-Guerin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells. Clin Exp Immunol 2006; 146: 181-188
37. Deshmane SL, Kremlev S, Amini S, Sawaya BE,. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009; 29: 313-326
38. Yamamoto K, Takeshima H, Hamada K, et al. Cloning and functional characterization of the 5′-flanking region of the human monocyte chemoattractant protein-1 receptor (CCR2) gene. Essential role of 5′-untranslated region in tissue-specific expression. J Biol Chem 1999; 274: 4646-4654
39. Rittig K, Peter A, Baltz KM, et al. The CCR2 promoter polymorphism T-960A, but not the serum MCP-1 level, is associated with endothelial function in prediabetic individuals. Atherosclerosis 2008; 198: 338-346
40. Wang M, Cheng G, Zhang Z, Fu G,. Genetic variants in the death receptor 4 gene contribute to susceptibility to bladder cancer. Mutat Res 2009; 661: 85-92
41. Collison A, Foster PS, Mattes J,. Emerging role of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) as a key regulator of inflammatory responses. Clin Exp Pharmacol Physiol 2009; 36: 1049-1053
42. Leibovici D, Grossman HB, Dinney CP, et al. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 2005; 23: 5746-5756
43. Ahirwar D, Kesarwani P, Manchanda PK, Mandhani A, Mittal RD,. Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guerin immunotherapy in bladder cancer. Cancer Genet Cytogenet 2008; 184: 1-8
44. Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 2009; 182: 2195-2203